I-Mab Appoints Kyler Lei as CFO and Reveals Upcoming Acquisition of VIS-101

Pending Acquisition: I-Mab is set to acquire VIS-101, a bifunctional biologic targeting VEGF-A and ANG2, through its new subsidiary Visara, with completion expected later this month.

Strategic Growth Plans: The company has reaffirmed its investment plans for givastomig and aims for a dual listing on NASDAQ and HKEX to enhance its global presence and investor base.

Leadership Changes: Kyler Lei has been appointed as CFO, and the company has strengthened its Board with experienced biotech executives to support its new strategy.

Clinical Development: I-Mab is optimistic about the potential of givastomig as a leading therapy for gastric cancer, with plans to initiate a global Phase 2 study in Q1 2026 following promising Phase 1b data.